Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹329 Cr
down ₹5 Cr vs Oct 2016
- Stocks held
- 26
- unchanged
- Top 10 weight
- 76.3%
- of the portfolio in its ten largest
- Cash & debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In November 2016 it disclosed 26 stocks worth ₹329 Cr, down ₹5 Cr from Oct 2016. Its largest positions were Sun Pharmaceutical Industries Limited (21.7%), Dr. Reddy's Laboratories Limited (11.3%), Lupin Limited (10.4%); the ten largest together made up 76.3% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 85.4% of its equity. Cash and debt stood at 1.8%. Compared with Oct 2016 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
10%
Holds more stocks than 10% of peers
Cash
27%
Holds more cash than 27% of peers
What these mean: concentration · cash
Holdings in November 2016
Download CSVEvery line the fund disclosed, with the change against Oct 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 21.71% | up 0.20 pts | ₹71.4 Cr | down ₹41 L | Trimmed |
| Dr. Reddy's Laboratories Limited | 11.34% | down 0.41 pts | ₹37.3 Cr | down ₹1.9 Cr | Trimmed |
| Lupin Limited | 10.38% | up 1.72 pts | ₹34.2 Cr | up ₹5.2 Cr | Added |
| Cipla Limited | 9.34% | up <0.01 pts | ₹30.7 Cr | down ₹46 L | Trimmed |
| Aurobindo Pharma Limited | 6.04% | down 0.48 pts | ₹19.9 Cr | down ₹1.9 Cr | Trimmed |
| Divi's Laboratories Limited | 4.63% | down 0.34 pts | ₹15.2 Cr | down ₹1.4 Cr | Trimmed |
| Piramal Enterprises Limited | 3.82% | down 0.12 pts | ₹12.5 Cr | down ₹60 L | Trimmed |
| Alkem Laboratories Limited | 3.81% | up 0.21 pts | ₹12.5 Cr | up ₹50 L | Added |
| Narayana Hrudayalaya Limited | 2.64% | up 0.04 pts | ₹8.7 Cr | up ₹1 L | Held |
| Zydus Lifesciences Limited | 2.63% | down 0.10 pts | ₹8.6 Cr | down ₹46 L | Trimmed |
| IPCA Laboratories Limited | 2.58% | down 0.09 pts | ₹8.5 Cr | down ₹42 L | Trimmed |
| Biocon Limited | 2.40% | up 0.01 pts | ₹7.9 Cr | down ₹8 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.37% | down 0.19 pts | ₹7.8 Cr | down ₹75 L | Trimmed |
| Syngene International Limited | 2.26% | up 0.03 pts | ₹7.4 Cr | down ₹0 L | Held |
| Strides Pharma Science Limited | 1.85% | up 0.11 pts | ₹6.1 Cr | up ₹27 L | Added |
| Cash, TREPS & receivables | 1.83% | down 0.53 pts | ₹6 Cr | down ₹1.9 Cr | Trimmed |
| Pfizer Limited | 1.62% | up 0.03 pts | ₹5.3 Cr | up ₹2 L | Held |
| Sanofi India Limited | 1.59% | up 0.06 pts | ₹5.2 Cr | up ₹12 L | Added |
| Unichem Laboratories Limited | 1.43% | down 0.10 pts | ₹4.7 Cr | down ₹39 L | Trimmed |
| Natco Pharma Limited | 1.11% | up 0.05 pts | ₹3.7 Cr | up ₹13 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 1.05% | down 0.06 pts | ₹3.5 Cr | down ₹25 L | Trimmed |
| Indraprastha Medical Corporation Limited | 1.01% | down 0.10 pts | ₹3.3 Cr | down ₹37 L | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.87% | down 0.01 pts | ₹2.9 Cr | down ₹7 L | Trimmed |
| Shilpa Medicare Limited | 0.61% | up 0.08 pts | ₹2 Cr | up ₹24 L | Added |
| Torrent Pharmaceuticals Limited | 0.60% | down 0.01 pts | ₹2 Cr | down ₹5 L | Trimmed |
| Indoco Remedies Limited | 0.35% | down 0.03 pts | ₹1.1 Cr | down ₹12 L | Trimmed |
| Thyrocare Technologies Limited | 0.15% | up 0.01 pts | ₹49 L | up ₹3 L | Added |
What changed, Oct 2016 to Nov 2016
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Lupin Limitedup ₹5.2 Cr (+1.72% pts)
- Alkem Laboratories Limitedup ₹50 L (+0.21% pts)
- Strides Pharma Science Limitedup ₹27 L (+0.11% pts)
- Shilpa Medicare Limitedup ₹24 L (+0.08% pts)
- Natco Pharma Limitedup ₹13 L (+0.05% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Oct 2016, the weight rose most in Pharmaceuticals & Biotechnology (+0.2 pts), and fell most in Finance (−0.1 pts).
- Pharmaceuticals & Biotechnology85.1% → 85.4%+0.2 pts
- Finance4.0% → 3.9%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Nov 2015 | May 2016 | Aug 2016 | Oct 2016 | Nov 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 88.2% | 85.2% | 86.4% | 85.1% | 85.4% |
| Healthcare Services | 2.9% | 5.7% | 5.4% | 6.2% | 6.2% |
| Pharmaceuticals | 5.9% | 4.8% | 4.1% | 4.6% | 4.6% |
| Finance | 3.0% | 4.3% | 4.1% | 4.0% | 3.9% |
Allocation in Nov 2016change vs Oct 2016
- Pharmaceuticals & Biotechnology (17)85.4%▲ 0.2 pts
- Healthcare Services (4)6.2%
- Pharmaceuticals (4)4.6%
- Finance (1)3.9%▼ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Nov 2016
1.8%
▼ 0.5 pts vs Oct 2016
- Cash alone
- 1.8%
- cash and net receivables
- A year earlier
- 12.6%
- Nov 2015 · now ▼ 10.8 pts
- Last 12 months
- 0.7% – 11.7%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.